| Updated:
Actelion profits are set to freeze
SWISS pharmaceutical giant Actelion said yesterday it expected profits in 2012 to remain at 2011 levels.
The company set a target for its earnings, to be unchanged from SFr437.5m (£303.4m) in 2011.
The Tracleer lung treatment is one of the company’s mainstays but it is facing ever increasing competition.
The company is working on a Macitentan, a new lung drug which is aimed at replacing Tracleer.
Actelion said it was upbeat about future prospects despite tough current market conditions.